Clinical Trials Using Montanide ISA 51 VG
Clinical trials are research studies that involve people. The clinical trials on this list are studying Montanide ISA 51 VG. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Vaccine (Galinpepimut-S) with Nivolumab for the Treatment of Patients with WT1-Expressing Malignant Pleural Mesothelioma
This phase I trial studies the side effects of a vaccine, galinpepimut-S, and nivolumab in treating patients with WT1 positive malignant pleural mesothelioma. Vaccines, such as galinpepimut-S, are made from Wilms Tumor Protein 1 (WT1) peptide and may help the body build an effective immune response to kill tumor cells that express WT1. Galinpepimut-S is mixed with a substance called montanide, which helps to boost the immune reaction to galinpepimut-S. The mixture of the galinpepimut-S and montanide make up the actual final vaccine that is then given to patients. Immunotherapy with monoclonal antibodies, such as nivolumab, may remove signals that block the immune system’s activity, indirectly strengthening the immune system to help fight the cancer. It has been shown that cancer vaccines can sometimes increase these signals that actually block the immune system’s anti-cancer activity. Using a cancer vaccine (galinpepimut-S) directed to mesothelioma cells with a drug that can unblock these negative signals (nivolumab) may help treat malignant pleural mesothelioma.
Location: 6 locations
Montanide and / or Poly-ICLC with Oxidized Tumor Cell Lysate Vaccine and Sargramostim in Treating Patients with Advanced Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized pilot early phase I trial studies montanide (montanide ISA 51 VG) and / or poly-ICLC with oxidized tumor cell lysate vaccine and sargramostim in treating patients with stage III-IV ovarian, primary peritoneal, or fallopian tube cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Biological therapies, such as montanide ISA 51 VG and poly-ICLC, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the production of blood cells. Giving montanide ISA 51 VG and / or poly-ICLC together with oxidized tumor cell lysate vaccine and sargramostim may be a better treatment for ovarian, primary peritoneal, or fallopian tube cancer.
Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania